Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

Jeffrey A. Cohen; Robert A. Bermel; Cynthia I. Grossman; Carrie M. Hersh; Megan Hyland; Ellen M. Mowry; Robert Naismith; Maria L. Naylor; Jacqueline Nicholas; Rajani Rajbhandar; Carol M. Singh; Mar Tintorè; Ana Zabalza; Tjalf Ziemssen; James R. Williams; Xavier Montalban

doi:10.1177/13524585211061343

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

Jeffrey A. Cohen
, Robert A. Bermel
, Cynthia I. Grossman
, Carrie M. Hersh
, Megan Hyland
, Ellen M. Mowry
, Robert Naismith
, Maria L. Naylor
, Jacqueline Nicholas
, Rajani Rajbhandar
, Carol M. Singh
, Mar Tintorè
, Ana Zabalza
, Tjalf Ziemssen
, James R. Williams
, Xavier Montalban

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Background: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Methods: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. Results: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group. Conclusion: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.

Original language	English
Pages (from-to)	1131-1137
Number of pages	7
Journal	Multiple Sclerosis Journal
Volume	28
Issue number	7
DOIs	https://doi.org/10.1177/13524585211061343
State	Published - Jun 2022

Keywords

MS PATHS
Multiple sclerosis
SARS-COV-2 vaccination
disease-modifying therapy
humoral immune response
optimal management

Access to Document

10.1177/13524585211061343

Cite this

Cohen, J. A., Bermel, R. A., Grossman, C. I., Hersh, C. M., Hyland, M., Mowry, E. M., Naismith, R., Naylor, M. L., Nicholas, J., Rajbhandar, R., Singh, C. M., Tintorè, M., Zabalza, A., Ziemssen, T., Williams, J. R., & Montalban, X. (2022). Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Multiple Sclerosis Journal, 28(7), 1131-1137. https://doi.org/10.1177/13524585211061343

@article{5cad72b84035490793cca8c3d4e780e8,

title = "Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions",

abstract = "Background: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Methods: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. Results: Three hundred twenty-two people with MS were included; 91.9\% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40\% for anti-CD20 (32/80 patients); 41\% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100\% for all other classes, including the no DMT group. Conclusion: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.",

keywords = "MS PATHS, Multiple sclerosis, SARS-COV-2 vaccination, disease-modifying therapy, humoral immune response, optimal management",

author = "Cohen, \{Jeffrey A.\} and Bermel, \{Robert A.\} and Grossman, \{Cynthia I.\} and Hersh, \{Carrie M.\} and Megan Hyland and Mowry, \{Ellen M.\} and Robert Naismith and Naylor, \{Maria L.\} and Jacqueline Nicholas and Rajani Rajbhandar and Singh, \{Carol M.\} and Mar Tintor{\`e} and Ana Zabalza and Tjalf Ziemssen and Williams, \{James R.\} and Xavier Montalban",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2022.",

year = "2022",

month = jun,

doi = "10.1177/13524585211061343",

language = "English",

volume = "28",

pages = "1131--1137",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

number = "7",

}

Cohen, JA, Bermel, RA, Grossman, CI, Hersh, CM, Hyland, M, Mowry, EM, Naismith, R, Naylor, ML, Nicholas, J, Rajbhandar, R, Singh, CM, Tintorè, M, Zabalza, A, Ziemssen, T, Williams, JR & Montalban, X 2022, 'Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions', Multiple Sclerosis Journal, vol. 28, no. 7, pp. 1131-1137. https://doi.org/10.1177/13524585211061343

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. / Cohen, Jeffrey A.; Bermel, Robert A.; Grossman, Cynthia I. et al.
In: Multiple Sclerosis Journal, Vol. 28, No. 7, 06.2022, p. 1131-1137.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

AU - Cohen, Jeffrey A.

AU - Bermel, Robert A.

AU - Grossman, Cynthia I.

AU - Hersh, Carrie M.

AU - Hyland, Megan

AU - Mowry, Ellen M.

AU - Naismith, Robert

AU - Naylor, Maria L.

AU - Nicholas, Jacqueline

AU - Rajbhandar, Rajani

AU - Singh, Carol M.

AU - Tintorè, Mar

AU - Zabalza, Ana

AU - Ziemssen, Tjalf

AU - Williams, James R.

AU - Montalban, Xavier

N1 - Publisher Copyright: © The Author(s), 2022.

PY - 2022/6

Y1 - 2022/6

N2 - Background: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Methods: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. Results: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group. Conclusion: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.

AB - Background: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Methods: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. Results: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group. Conclusion: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.

KW - MS PATHS

KW - Multiple sclerosis

KW - SARS-COV-2 vaccination

KW - disease-modifying therapy

KW - humoral immune response

KW - optimal management

UR - https://www.scopus.com/pages/publications/85122656213

U2 - 10.1177/13524585211061343

DO - 10.1177/13524585211061343

M3 - Article

C2 - 34994577

AN - SCOPUS:85122656213

SN - 1352-4585

VL - 28

SP - 1131

EP - 1137

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 7

ER -

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this